Clot Waveform Analysis for Monitoring Hemostasis

被引:6
作者
Nogami, Keiji [1 ]
机构
[1] Nara Med Univ, Dept Pediat, 840 Shijo Cho, Kashihara, Nara 6348522, Japan
关键词
activated partial thromboplastin time; clot waveform analysis; coagulation; fibrinolysis; hemophilia; HEMOPHILIA-A PATIENTS; PARTIAL THROMBOPLASTIN TIME; DISSEMINATED INTRAVASCULAR COAGULATION; FACTOR-VIII ACTIVITY; THROMBIN GENERATION; VERY-LOW; PHENOTYPIC HETEROGENEITY; INTERNATIONAL-SOCIETY; FACTOR-IX; APTT;
D O I
10.1055/s-0042-1756706
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Clot waveform analysis (CWA) is a recently developed global coagulation assessment, based on the continuous observation of changes in light transmittance, absorbance, or light scattering that occurs as fibrin formed in a plasma sample during routine clotting tests such as activated partial thromboplastin time (aPTT) and prothrombin time (PT). CWA can utilize qualitative waveform patterns as well as sensitive quantitative parameters and can be used as a simple method to assess global hemostasis, and can be applied to various challenging clinical situations. Although not all coagulation analyzers currently in use are able to provide CWA, the number of analyzers available to do so is increasing, as the usefulness of this process has become more widely recognized. CWA can be based on the coagulation mechanism of aPTT, an intrinsic trigger, and this has been reported in many studies, including diagnosis and treatment of patients with hemophilia, disseminated intravascular coagulation, and monitoring of anticoagulants and thrombosis. CWA using trace amounts of tissue factors also has the potential to expand the applications of this technology. Recently, there have been reports of the combined evaluation of fibrinolytic dynamics. Among the existing global coagulation assays, CWA may prove to be the easiest to standardize in clinical practice. However, more extensive testing using standardized methods in various clinical settings is needed to determine the true role of CWA in the evaluation of hemostasis and thrombosis in the future.
引用
收藏
页码:592 / 599
页数:8
相关论文
共 54 条
[11]   Effectiveness of factor VIII infusions in haemophilia A patients with high responding inhibitors [J].
Kasuda, S ;
Tanaka, I ;
Shima, M ;
Matsumoto, T ;
Sakurai, Y ;
Nishiya, K ;
Giles, AR ;
Yoshioka, A .
HAEMOPHILIA, 2004, 10 (04) :341-346
[12]   A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model [J].
Kitazawa, Takehisa ;
Igawa, Tomoyuki ;
Sampei, Zenjiro ;
Muto, Atsushi ;
Kojima, Tetsuo ;
Soeda, Tetsuhiro ;
Yoshihashi, Kazutaka ;
Okuyama-Nishida, Yukiko ;
Saito, Hiroyuki ;
Tsunoda, Hiroyuki ;
Suzuki, Tsukasa ;
Adachi, Hideki ;
Miyazaki, Taro ;
Ishii, Shinya ;
Kamata-Sakurai, Mika ;
Iida, Takeo ;
Harada, Aya ;
Esaki, Keiko ;
Funaki, Miho ;
Moriyama, Chifumi ;
Tanaka, Eriko ;
Kikuchi, Yasufumi ;
Wakabayashi, Tetsuya ;
Wada, Manabu ;
Goto, Masaaki ;
Toyoda, Takeshi ;
Ueyama, Atsunori ;
Suzuki, Sachiyo ;
Haraya, Kenta ;
Tachibana, Tatsuhiko ;
Kawabe, Yoshiki ;
Shima, Midori ;
Yoshioka, Akira ;
Hattori, Kunihiro .
NATURE MEDICINE, 2012, 18 (10) :1570-U177
[13]   Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) [J].
Knoebl, P. ;
Marco, P. ;
Baudo, F. ;
Collins, P. ;
Huth-Kuhne, A. ;
Nemes, L. ;
Pellegrini, F. ;
Tengborn, L. ;
Levesque, H. ;
Aspoek, G. ;
Heistinger, M. ;
Knobl, P. ;
Makipernaa, A. ;
Andre, H. ;
Aouba, A. ;
Bellucci, Sylvia ;
Beurrier, P. ;
Borg, J. Y. ;
Darnige, L. ;
Devignes, J. ;
D'Oiron, R. ;
Gautier, P. ;
Gay, V. ;
Girault, S. ;
Gruel, Y. ;
Guerin, V. ;
Hezard, N. ;
Khellaf, M. ;
Koenig, M. ;
Lifermann, F. ;
Marlu, R. ;
Ninet, Jacques ;
Peynet, J. ;
Quemeneur, T. ;
Rothschild, C. ;
Schleinitz, N. ;
Sigaud, M. ;
Trouillier, S. ;
Voisin, S. ;
Giebl, A. ;
Holstein, K. ;
Loreth, R. M. ;
Steigerwald, U. ;
Tiede, A. ;
Theodossiades, G. ;
Radvanyi, G. ;
Schlammadinger, A. ;
Barillari, G. ;
Pasca, S. ;
Baudo, F. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (04) :622-631
[14]   Analysis of the activated partial thromboplastin time test using mathematical modeling [J].
Kogan, AE ;
Kardakov, DV ;
Khanin, MA .
THROMBOSIS RESEARCH, 2001, 101 (04) :299-310
[15]  
Levi M, 2009, BRIT J HAEMATOL, V145, P24, DOI [10.1111/j.1365-2141.2009.07600.x, 10.1111/j.1365-2141.2008.07445.x]
[16]   The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay [J].
Matsumoto, T ;
Shima, M ;
Takeyama, M ;
Yoshida, K ;
Tanaka, I ;
Sakurai, Y ;
Giles, AR ;
Yoshioka, A .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (02) :377-384
[17]   Clot waveform analysis using CS-2000i™ distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A [J].
Matsumoto, T. ;
Nogami, K. ;
Tabuchi, Y. ;
Yada, K. ;
Ogiwara, K. ;
Kurono, H. ;
Arai, N. ;
Shima, M. .
HAEMOPHILIA, 2017, 23 (05) :e427-e435
[18]   Coagulation function and mechanisms in various clinical phenotypes of patients with acquired factor V inhibitors [J].
Matsumoto, T. ;
Nogami, K. ;
Shima, M. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (09) :1503-1512
[19]   A combined approach using global coagulation assays quickly differentiates coagulation disorders with prolonged aPTT and low levels of FVIII activity [J].
Matsumoto, Tomoko ;
Nogami, Keiji ;
Shima, Midori .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (02) :174-183
[20]   A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies [J].
Matsumoto, Tomoko ;
Nogami, Keiji ;
Ogiwara, Kenichi ;
Shima, Midori .
THROMBOSIS AND HAEMOSTASIS, 2012, 107 (02) :288-301